Citi analyst David Lebowitz lowered the firm’s price target on Intellia Therapeutics to $29 from $31 and keeps a Neutral rating on the shares post the Q1 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
- Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
- Intellia Therapeutics to present updated data from Phase 1/2 study of NTLA-2002
- Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
- Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call